From discovery to development and commercialisation, we have the defining science, cost-effective drug development capabilities and significant manufacturing capacity to move ideas to market.

Leveraging India’s globally competitive cost base and exceptional scientific people resource, we are advancing our in-house R&D programs, while also providing custom and clinical research services to international pharmaceutical and biotechnology majors through our subsidiary companies, Syngene and Clinigene.

Biocon has rapidly developed a robust drug pipeline, led by monoclonal antibodies and several other molecules at exciting stages in the biopharmaceutical value chain. With the successful commercial launch of our first anti-cancer drug and several promising discovery partnerships in the clinic, we remain committed to scaling new heights in frontier science and achieving new milestones in affordable medicine.

Our biosimilar insulin, an outcome of incremental innovation, is one of the world's most affordable therapies for insulin dependent diabetes. Bio-generic monoclonal antibodies are forming the core of our evolutionary innovation strategy. In the more challenging area of experimental innovation, Biocon is at the cutting edge. We are developing conjugated antibodies with a US Biotech start-up, IATRICa, to potentially deliver therapeutic cancer vaccines. We are also pursuing a path of breakthrough innovation through phase III human clinical trials to develop the world's first Oral Insulin. Biocon is thus rapidly moving towards commercializing novel biologics with a "Made in India" label.

Core Sales Territory: Global Regulated Markets

Core Operation: API Manufacture, Finished Dose Manufacture, Sales and Marketing, Distribution

Number of molecules sold: > 100

Company's rating: